# Vinorelbine and Gemcitabine Versus Capecitabine in Pretreated Metastatic Breast Cancer

> **NCT00431106** · PHASE3 · COMPLETED · sponsor: **Hellenic Oncology Research Group** · enrollment: 144 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Capecitabine
- **DRUG:** Vinorelbine

## Key facts

- **NCT ID:** NCT00431106
- **Lead sponsor:** Hellenic Oncology Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2009-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00431106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00431106, "Vinorelbine and Gemcitabine Versus Capecitabine in Pretreated Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00431106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*